David Lamond, Director at Quince Therapeutics, Inc. (QNCX), bought 43,134 shares at $0.90 ($41K) on 2023-11-30, disclosed to the SEC on 2023-12-01.
Open-market purchase of $41k QNCX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.98 | 14,378 | $14K | 34.8% |
| 2 | $0.90 | 14,378 | $13K | 31.9% |
| 3 | $0.94 | 14,378 | $14K | 33.3% |
| Total | $0.94 avg | 43,134 | $41K | 100% |
| Filing → |
| QNCX | BUY | 2023-08-31 | $216K | — | Filing → |
| QNCX | BUY | 2023-08-17 | $620K | — | Filing → |
| AMTI | BUY | 2022-05-23 | $211K | — | Filing → |